Target Organs and Levels of Evidence for TR-558
Toxicology and Carcinogenesis Studies of 3,3',4,4'-Tetrachloroazobenzene (CASRN 14047-09-7) in Harlan Sprague-Dawley Rats and B6C3F1 Mice (Gavage Studies)
Chemical (Study Title) CASRN |
Peer Review Date |
Route/Exposure Levels |
Study Laboratory |
3,3',4,4'-Tetrachloroazobenzene 14047-09-7 |
02/25/2009 |
Gavage 0, .1, .3, 1, 10, 30, OR 100 MG/KG; 10/SEX/DOSE |
Battelle Columbus Laboratory |
Levels of Evidence: None
Chemical (Study Title) CASRN |
Peer Review Date |
Primary Uses |
Route/Exposure Levels |
Study Laboratory |
3,3',4,4'-Tetrachloroazobenzene 14047-09-7 |
02/25/2009 |
Impurity in dichloroaniline and herbicides derived from DCA. 3,3',4,4'-TCAB is not commercially manufactured but is formed as an unwanted byproduct in the manufacture of 3,4-DCA & its herbicidal derivatives. In addition, environmental contamination by 3,3',4,4'-TCAB occurs from the degradation of chloranilide herbicides & the photolysis and biolysis of 3,4-DCA. |
Gavage R: 0, 10, 30, OR 100 MG/KG AND M: 0, 3, 10, OR 30 MG/KG; 50/SEX/SPECIES/DOSE |
Battelle Columbus Laboratory |
Levels of Evidence
Male Rats: Clear Evidence
Type |
Organ/Tissue (Lesion) |
Neoplastic Lesions |
- Lung: Cystic keratinizing epithelioma 0/50 14/50 31/50 37/50
- Liver: Cholangiocarcinoma 0/50 4/50 4/50 6/50
- Oral Cavity: Mucosa: Gingival squamous cell carcinoma 1/50 5/50 4/50 5/50
- Thyroid Gland: Follicular cell adenoma 0/50 3/50 4/50 4/50
|
May Have Been Related |
- Thoracic Cavity: Malignant Schwannoma: 0/50 0/50 1/50 3/50
|
Non-Neoplastic Lesions |
- Lung: Pigmentation; alveolar epithelium metaplasia, squamous; alveolar epithelium, metaplasia, bronchiolar; alveolus infiltration cellular, histiocyte
- Liver: Hepatocyte hypertrophy; centrilobular degeneration; necrosis; pigmentation; diffuse fatty change; oval cell hyperplasia; hematopoietic cell proliferation; eosinophilic focus; bile duct cyst; toxic hepatopathy
- Oral Mucosa: Gingival squamous hyperplasia; gingival cystic keratinizing hyperplasia
- Thyroid Gland: Follicular cell hypertrophy; follicular cell hyperplasia; inflammation
- Forestomach: Epithelium, hyperplasia
- Adrenal Cortex: Degeneration; cytoplasmic vacuolization; zona fasciculata, hyperplasia; necrosis
- Pancreas: Atrophy; acinar cytoplasmic vacuolization; inflammation
- Blood Vessel: Inflammation
- Spleen: Lymphoid follicle atrophy
- Lymph Node, Mesenteric: Pigmentation; atrophy
- Testis: Germinal epithelial degeneration
|
Female Rats: Clear Evidence
Type |
Organ/Tissue (Lesion) |
Neoplastic Lesions |
- Lung: Cystic keratinizing epithelioma 0/50 6/50 26/49 39/49
- Liver: Cholangiocarcinoma 1/50 1/50 1/49 3/49
- Oral Cavity: Mucosa: Gingival squamous cell carcinoma 0/50 0/50 4/50 6/50
- Forestomach: Squamous cell papilloma or carcinoma 0/50 1/50 0/50 4/50
|
May Have Been Related |
- Adrenal Gland Cortex: Ademona 1/50 1/50 3/50 4/49
|
Non-Neoplastic Lesions |
- Lung: Pigmentation; alveolar epithelium, metaplasia, squamous; alveolar epithelium, metaplasia, bronchiolar
- Liver: Hepatocyte hypertrophy; centrilobular degeneration; necrosis; pigmentation; focal fatty change; diffuse fatty change; bile duct hyperplasia; oval cell hyperplasia; nodular hyperplasia; hematopoietic cell proliferation; eosinophilic focus; mixed cell focus; bile duct cyst; multinucleated hepatocyte; toxic hepatopathy; cholangiofibrosis
- Oral Mucosa: Gingival squamous hyperplasia; gingival cystic keratinizing hyperplasia
- Forestomach: Epithelium, hyperplasia
- Adrenal Cortex: Cytoplasmic vacuolization; zona fasciculata, hyperplasia
- Pancreas: Atrophy; acinar cytoplasmic vacuolization
- Blood Vessel: Inflammation
- Spleen: Lymphoid follicle atrophy; pigmentation
- Lymph Node, Mesenteric: Pigmentation; atrophy
- Nasal Cavity: Inflammation
|
Male Mice: Clear Evidence
Type |
Organ/Tissue (Lesion) |
Neoplastic Lesions |
- Urinary System: Urethra: Transitional epithelial gland carcinoma 0/50 32/50 46/49 49/50
- Lung: Alveolar/bronchiolar adenoma 5/50 16/50 12/49 6/50 alveolar/bronchiolar adenoma or carcinoma 7/50 17/50 15/49 6/50
- Forestomach: Squamous cell carcinoma 0/50 1/50 1/49 3/50
|
May Have Been Related |
- Ureter: Transitional epithelial carcinoma: 0/43 0/45 1/47 0/50
|
Non-Neoplastic Lesions |
- Urethra: Transitional epithelial gland hyperplasia
- Ureter: Dilatation; chronic active inflammation
- Urinary Bladder: Transitional epithelial hyperplasia
- Forestomach: Epithelial hyperplasia
- Glandular Stomach: Focal epithelial hyperplasia; gland epithelium cyst; lymphoid cellular infiltration; mineralization
- Skin: Chronic active inflammation; dermal fibrosis; epidermal hyperplasia; epidermal ulcer; hair follicle dilatation; sebaceous gland atrophy
- Spleen: Atrophy
- Thymus: Atrophy
- Liver: Hematopoietic cell proliferation
- Heart: Cardiomyopathy
- Blood Vessel: Aorta mineralization
|
Female Mice: Clear Evidence
Type |
Organ/Tissue (Lesion) |
Neoplastic Lesions |
- Skin: Fibrosarcoma 1/50 6/50 5/50 8/50 fibrosarcoma or malignant schwannoma 2/50 8/50 7/50 12/50
- Urinary System: Urethra: Transitional epithelial gland carcinoma 0/50 0/50 0/50 2/50
- Lung: Alveolar/bronchiolar adenoma or carcinoma 0/49 2/50 1/50 4/50 alveolar/bronchiola adenoma or carcinoma 3/49 8/50 5/50 10/50 cystic keratinizing epithelioma 0/49 0/50 0/50 2/50
- Forestomach: Squamous cell carcinoma 0/50 1/50 1/50 4/50
|
May Have Been Related |
- All Organs: Malignant Lymphoma: 2/50 5/50 8/50 7/50
- Ureter: Transitional epithelial carcinoma: 0/0 0/1 0/0 1/2
|
Non-Neoplastic Lesions |
- Urinary Bladder: Transitional epithelial hyperplasia
- Lung: Chronic active inflammation
- Forestomach: Epithelial hyperplasia
- Glandular Stomach: Focal epithelial hyperplasia; gland epithelial cyst; lymphoid cellular infiltration
- Skin: Chronic active inflammation; dermal fibrosis; epidermal hyperplasia epidermal ulcer; hair follicle dilatation; sebaceous gland atrophy
- Clitoral Gland: Atrophy; duct cyst; chronic inflammation
- Ovary: Atrophy
- Bone Marrow: Hyperplasia
- Spleen: Hematopoietic cell proliferation
- Thymus: Atrophy
- Liver: Hematopoietic cell proliferation
- Heart: Cardiomyopathy
|